All News Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.75 ^USD	-2.58%		-9.93%	-74.40%

Mar. 15	North American Morning Briefing : Inflation -2-	DJ
Mar. 14	Top Midday Decliners	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates	May. 13	BU
Spruce Biosciences : Pediatric Endocrine Society 2024 Annual Meeting	May. 03	PU
Spruce Biosciences : Failure to Satisfy Listing Rule - Form 8-K	May. 02	PU
Spruce Biosciences to Participate in May Investor Conferences	May. 01	BU
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	Apr. 30	BU
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	Apr. 22	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	Apr. 04	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	Mar. 27	PR
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 21	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	Mar. 19	PR
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 14	BU
Top Midday Decliners	Mar. 14	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	Mar. 14	MT
HC Wainwright Downgrades Spruce Biosciences to Neutral From Buy	Mar. 14	MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $3 From $8, Maintains Market Outperform Rating	Mar. 14	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Mar. 14	MT
Leerink Partners Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $9	Mar. 14	MT
Guggenheim Downgrades Spruce Biosciences to Neutral From Buy	Mar. 14	MT
Ladenburg Thalmann Downgrades Spruce Biosciences to Neutral From Buy	Mar. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

All News

Filters